Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study.
Adiponectin
/ blood
Antibodies, Monoclonal, Humanized
/ therapeutic use
Antirheumatic Agents
/ therapeutic use
Arthritis, Rheumatoid
/ drug therapy
Body Weight
/ drug effects
Drug Therapy, Combination
Female
Heart Disease Risk Factors
Humans
Leptin
/ blood
Male
Methotrexate
/ therapeutic use
Middle Aged
Receptors, Interleukin-6
/ antagonists & inhibitors
Resistin
/ blood
Retrospective Studies
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
Adipokine
Interleukin-6 Receptor Inhibition
Rheumatoid Arthritis
Weight Gain
Journal
Journal of Korean medical science
ISSN: 1598-6357
Titre abrégé: J Korean Med Sci
Pays: Korea (South)
ID NLM: 8703518
Informations de publication
Date de publication:
08 Jun 2020
08 Jun 2020
Historique:
received:
17
12
2019
accepted:
27
03
2020
entrez:
9
6
2020
pubmed:
9
6
2020
medline:
11
3
2021
Statut:
epublish
Résumé
Causes of weight change after tocilizumab treatment are unclear. We aimed to investigate the effects of tocilizumab treatment on body weight and serum adipokine levels in patients with rheumatoid arthritis (RA). In this retrospective cohort study, we evaluated weight changes in patients with RA who received methotrexate (Cohort I) or tocilizumab with methotrexate (Cohorts II and III) for 24 weeks. Adipokine concentrations at baseline and 24 weeks were analyzed in Cohorts I and III. Cohorts I and II received tocilizumab therapy for an additional 48 weeks, during which weight changes were monitored (24-72 weeks). No significant weight change occurred after 24 weeks of methotrexate treatment (mean difference, -0.2 kg; Weight and the leptin-adiponectin ratio increased after tocilizumab treatment. Given that cardiovascular (CV) risk factors may deteriorate in patients with RA who receive tocilizumab, further studies are required to determine the effects of weight gain on CV outcomes in these patients.
Sections du résumé
BACKGROUND
BACKGROUND
Causes of weight change after tocilizumab treatment are unclear. We aimed to investigate the effects of tocilizumab treatment on body weight and serum adipokine levels in patients with rheumatoid arthritis (RA).
METHODS
METHODS
In this retrospective cohort study, we evaluated weight changes in patients with RA who received methotrexate (Cohort I) or tocilizumab with methotrexate (Cohorts II and III) for 24 weeks. Adipokine concentrations at baseline and 24 weeks were analyzed in Cohorts I and III. Cohorts I and II received tocilizumab therapy for an additional 48 weeks, during which weight changes were monitored (24-72 weeks).
RESULTS
RESULTS
No significant weight change occurred after 24 weeks of methotrexate treatment (mean difference, -0.2 kg;
CONCLUSION
CONCLUSIONS
Weight and the leptin-adiponectin ratio increased after tocilizumab treatment. Given that cardiovascular (CV) risk factors may deteriorate in patients with RA who receive tocilizumab, further studies are required to determine the effects of weight gain on CV outcomes in these patients.
Identifiants
pubmed: 32508063
pii: 35.e155
doi: 10.3346/jkms.2020.35.e155
pmc: PMC7279943
doi:
Substances chimiques
Adiponectin
0
Antibodies, Monoclonal, Humanized
0
Antirheumatic Agents
0
IL6R protein, human
0
Leptin
0
RETN protein, human
0
Receptors, Interleukin-6
0
Resistin
0
Tumor Necrosis Factor-alpha
0
tocilizumab
I031V2H011
Methotrexate
YL5FZ2Y5U1
Banques de données
ClinicalTrials.gov
['NCT01211834', 'NCT01256736']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e155Subventions
Organisme : Chungbuk National University Hospital
Pays : Korea
Organisme : Ministry of Science, ICT and Future Planning
ID : NRF-2015M3A9B6052011
Pays : Korea
Organisme : Ministry of Science, ICT and Future Planning
ID : 2019M3A9A8065574
Pays : Korea
Organisme : Ministry of Health and Welfare
ID : HI14C1277
Pays : Korea
Informations de copyright
© 2020 The Korean Academy of Medical Sciences.
Déclaration de conflit d'intérêts
IA Choi received a research grant from Chungbuk National University Hospital in 2018. She received a research grant from LG Chem and AbbVie Korea, which is not relevant to this study. EY Lee received the grants from the Ministry of Science, ICT and Future planning (NRF-2019M3A9A8065574). EB Lee has received research grants from Pfizer Korea, and has been a consultant for Pfizer. YW Song received a research grant from JW Pharmaceuticals during the clinical trials (NCT01211834 and NCT01256736). The use of clinical data and serum samples in this study were supported by JW Pharmaceuticals. The present study received grants from the Ministry of Science, ICT and Future planning (NRF-2015M3A9B6052011, 2019M3A9A8065574) and a grant from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (HI14C1277).
Références
Nat Med. 1995 Nov;1(11):1155-61
pubmed: 7584987
Ann Rheum Dis. 2010 Nov;69(11):1920-5
pubmed: 20444756
Ann Rheum Dis. 2011 Sep;70(9):1562-8
pubmed: 21571734
Endocr Rev. 2005 May;26(3):439-51
pubmed: 15897298
Clin Rheumatol. 2009 Apr;28(4):445-51
pubmed: 19085030
Nat Rev Immunol. 2006 Oct;6(10):772-83
pubmed: 16998510
Curr Med Chem. 2015;22(16):1903-10
pubmed: 25876749
Ann Rheum Dis. 2015 Apr;74(4):694-702
pubmed: 24368514
Nat Rev Rheumatol. 2010 Aug;6(8):445-51
pubmed: 20647995
Ann Rheum Dis. 2017 Jan;76(1):17-28
pubmed: 27697765
Arthritis Care Res (Hoboken). 2014 Sep;66(9):1296-301
pubmed: 24497371
RMD Open. 2019 Jul 21;5(2):e000897
pubmed: 31413865
Clin Exp Rheumatol. 2009 Mar-Apr;27(2):222-8
pubmed: 19473561
Metabolism. 2005 Mar;54(3):281-6
pubmed: 15736103
Nat Rev Rheumatol. 2011 Aug 02;7(9):528-36
pubmed: 21808287
Z Rheumatol. 2016 Dec;75(10):1021-1027
pubmed: 26820722
Intern Med. 2011;50(4):269-75
pubmed: 21325757
J Rheumatol. 2011 Mar;38(3):406-8
pubmed: 21362777
Korean J Intern Med. 2019 Jul;34(4):917-931
pubmed: 29334721
Ann Rheum Dis. 2006 Sep;65(9):1198-201
pubmed: 16414972
Semin Arthritis Rheum. 2015 Feb;44(4):381-8
pubmed: 25300699
Autoimmunity. 2016 Dec;49(8):547-553
pubmed: 27690205
Arthritis Rheumatol. 2020 Jan;72(1):31-40
pubmed: 31469238
Nat Rev Rheumatol. 2009 Dec;5(12):677-84
pubmed: 19901918
Adipocyte. 2018 Jan 2;7(1):57-62
pubmed: 29205099
Ann Rheum Dis. 2016 Oct;75(10):1806-12
pubmed: 26613768
Nat Rev Rheumatol. 2014 Nov;10(11):691-6
pubmed: 25090948
Am J Cardiol. 2011 Nov 1;108(9):1362-70
pubmed: 21855836
Ann Rheum Dis. 2016 Oct;75(10):1813-8
pubmed: 26792814
Arthritis Rheum. 2001 May;44(5):1170-6
pubmed: 11352251
Rheumatology (Oxford). 2009 Oct;48(10):1309-13
pubmed: 19696061
J Rheumatol. 2009 Apr;36(4):724-30
pubmed: 19273452
Mediators Inflamm. 2013;2013:710928
pubmed: 23431244
Ann Rheum Dis. 2010 Sep;69(9):1687-90
pubmed: 19640853
Clin Exp Rheumatol. 2019 Mar-Apr;37(2):293-300
pubmed: 30148441
Fundam Clin Pharmacol. 2009 Oct;23(5):595-600
pubmed: 19563510
Ann Rheum Dis. 2015 Mar;74(3):480-9
pubmed: 25561362
Arthritis Rheumatol. 2017 Jun;69(6):1154-1164
pubmed: 28245350
Joint Bone Spine. 2016 Mar;83(2):127-33
pubmed: 26184539
J Rheumatol. 2008 May;35(5):936-8
pubmed: 18464318
Arthritis Rheumatol. 2015 Jul;67(7):1711-7
pubmed: 25940140
Nat Rev Rheumatol. 2013 Sep;9(9):513-23
pubmed: 23774906
Rheumatology (Oxford). 2009 Jan;48(1):78-82
pubmed: 19056800
Arthritis Res Ther. 2010;12(5):R197
pubmed: 20964833
Ann Rheum Dis. 2011 Jun;70(6):929-34
pubmed: 21389043
Metabolism. 2006 Sep;55(9):1248-54
pubmed: 16919546
Ann Rheum Dis. 2011 Mar;70(3):482-7
pubmed: 21216812
Arthritis Res Ther. 2018 Aug 7;20(1):171
pubmed: 30086795
Ir J Med Sci. 2014 Dec;183(4):659-66
pubmed: 24510478